Changchun BCHT HSV-2 mRNA vaccine

Changchun BCHT is sponsoring a first-in-human Phase 1 study of an experimental preventive HSV-2 mRNA vaccine in China. The public ClinicalTrials.gov record does not give the vaccine a candidate name, so HSVHQ does not assign one.

The study began in October 2025 and was listed as enrolling by invitation when the record was last verified in January 2026. Its estimated enrollment is 144 healthy adults, and no results have been posted.

Chinese company and trial records probably connect this study with the name LVRNA101 and Chinese registry number CTR20252798, but no checked authoritative record directly cross-references those identifiers to NCT07330440. HSVHQ therefore treats that crosswalk as probable, not confirmed.

The program is intended to prevent HSV-2 infection or disease using an mRNA vaccine. The checked registry establishes the platform and preventive purpose but does not disclose the encoded antigens or full formulation.

Changchun BCHT says the vaccine uses a multi-component design and reported preclinical immune-response and HSV-1 cross-protection observations. Those are developer statements: HSVHQ did not identify a checked primary preclinical paper or dataset that would allow independent evaluation.

The Phase 1 study is designed primarily to assess safety and tolerability after vaccination in healthy adults aged 18 to 55.

Its title also names immunogenicity, meaning measured immune responses, as an objective. The public outcomes section checked by HSVHQ listed adverse-event and laboratory measures but did not provide a corresponding detailed immunogenicity endpoint.

Changchun BCHT and Zhuhai LiveRNA jointly received Chinese authorization in December 2024 to begin clinical testing of a preventive HSV-2 mRNA vaccine identified in that filing as LVRNA101.

NCT07330440 records an actual study start on October 13, 2025. Changchun BCHT's August 2026 half-year report also described the Phase 1 study as under way.

The registry plans a randomized, double-blind, placebo-controlled dose-escalation study. Its estimated primary completion is March 2027 and estimated overall completion is June 2027; these are planning dates, not predictions of results or approval.

There are no public human findings yet. ClinicalTrials.gov had no posted results, and no PubMed-indexed paper was identified under NCT07330440 or LVRNA101 through September 5, 2026.

The developer's preclinical statements cannot establish safety, immune response, prevention, or cross-protection in people. They also cannot substitute for the planned Phase 1 results.

The most defensible evidence-maturity label is early human evidence: dosing has begun in a registered Phase 1 study, but no human result is public.

Authorization to run a first-in-human trial means regulators allowed the study to proceed under its protocol. It does not establish that the vaccine works, that it has an acceptable safety profile, or that it will reach later phases.

The program is not an approved or available HSV vaccine in the checked evidence.

The current stage is Phase 1. NCT07330440 was enrolling by invitation when last verified by the sponsor in January 2026, and Changchun BCHT described the study as ongoing in an August 2026 filing.

No separate later-phase HSV study sponsored by Changchun BCHT was identified in the checked ClinicalTrials.gov route.

The next evidence-changing milestone is a complete public Phase 1 report, especially protocol-defined safety and immunogenicity results with participant flow and dose-group detail.

A later-phase plan should be treated as real only when a regulator or trial registry documents that it has been authorized and initiated; estimated Phase 1 dates alone do not establish that progression.